Literature DB >> 26965014

Reply to 'Comments on Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'.

Y Yang1, C Bailey2, F G Holz3, N Eter4, M Weber5, C Baker6, S Kiss7, U Menchini8, J M Ruiz Moreno9, P Dugel10, A Lotery11.   

Abstract

Entities:  

Year:  2016        PMID： 26965014      PMCID： PMC4941057          DOI： 10.1038/eye.2016.33

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  4 in total

1.  Comments on 'Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants'.

Authors:  B Takkar; S Azad
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

2.  Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Authors:  Peter A Campochiaro; David M Brown; Andrew Pearson; Thomas Ciulla; David Boyer; Frank G Holz; Michael Tolentino; Amod Gupta; Lilianne Duarte; Steven Madreperla; John Gonder; Barry Kapik; Kathleen Billman; Frances E Kane
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

3.  Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.

Authors:  Y Yang; C Bailey; F G Holz; N Eter; M Weber; C Baker; S Kiss; U Menchini; J M Ruiz Moreno; P Dugel; A Lotery
Journal:  Eye (Lond)       Date:  2015-06-26       Impact factor: 3.775

4.  Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.

Authors:  Ibrahim Elaraoud; Walter Andreatta; Andrej Kidess; Ajay Bhatnagar; Marie Tsaloumas; Fahad Quhill; Yit Yang
Journal:  BMC Ophthalmol       Date:  2016-01-05       Impact factor: 2.209
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.